PL2733493T3 - Sposób prognozowania in vitro progresji nowotworu i rezultatu u pacjenta oraz środki do przeprowadzenia wymienionego sposobu - Google Patents

Sposób prognozowania in vitro progresji nowotworu i rezultatu u pacjenta oraz środki do przeprowadzenia wymienionego sposobu

Info

Publication number
PL2733493T3
PL2733493T3 PL14154679.6T PL14154679T PL2733493T3 PL 2733493 T3 PL2733493 T3 PL 2733493T3 PL 14154679 T PL14154679 T PL 14154679T PL 2733493 T3 PL2733493 T3 PL 2733493T3
Authority
PL
Poland
Prior art keywords
prognosis
cancer
patient
outcome
progression
Prior art date
Application number
PL14154679.6T
Other languages
English (en)
Inventor
Jérôme Galon
Franck Pages
Wolf-Herman Fridman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36129834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2733493(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of PL2733493T3 publication Critical patent/PL2733493T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL14154679.6T 2005-10-19 2006-09-28 Sposób prognozowania in vitro progresji nowotworu i rezultatu u pacjenta oraz środki do przeprowadzenia wymienionego sposobu PL2733493T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05292200A EP1777523A1 (en) 2005-10-19 2005-10-19 An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
US76435606P 2006-02-02 2006-02-02

Publications (1)

Publication Number Publication Date
PL2733493T3 true PL2733493T3 (pl) 2016-12-30

Family

ID=36129834

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14154679.6T PL2733493T3 (pl) 2005-10-19 2006-09-28 Sposób prognozowania in vitro progresji nowotworu i rezultatu u pacjenta oraz środki do przeprowadzenia wymienionego sposobu

Country Status (8)

Country Link
US (5) US8481271B2 (pl)
EP (14) EP1777523A1 (pl)
JP (3) JP5256038B2 (pl)
AT (1) ATE523786T1 (pl)
DK (2) DK2733493T3 (pl)
ES (12) ES2470165T3 (pl)
PL (1) PL2733493T3 (pl)
WO (1) WO2007045996A1 (pl)

Families Citing this family (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120064089A1 (en) * 2002-11-15 2012-03-15 Morehouse School Of Medicine Anti-cxcl16 and anti-cxcr6 antibodies for the prevention and treatment of cancer and cancer cell migration
US8512701B2 (en) 2002-11-15 2013-08-20 Morehouse School Of Medicine Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration
US20120135415A1 (en) * 2002-11-15 2012-05-31 Morehouse School Of Medicine Detecting cancer with anti-cxcl13 and anti-cxcr5 antibodies
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
ES2539042T3 (es) * 2006-06-02 2015-06-25 Glaxosmithkline Biologicals S.A. Procedimiento de identificación de si un paciente será respondedor o no a inmunoterapia
ATE503025T1 (de) * 2006-07-14 2011-04-15 Us Gov Health & Human Serv Verfahren zur bestimmung der prognose eines adenokarzinoms
AR064333A1 (es) 2006-12-14 2009-04-01 Schering Corp Anticuerpo anti-tslp de diseno
CN101971033A (zh) * 2007-06-04 2011-02-09 戴诺普雷克斯公司 用于结直肠癌的生物标志物组合
GB0718167D0 (en) * 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
GB0723179D0 (en) * 2007-11-27 2008-01-02 Immunovia Ab Diagnostic methods and arrays for use in the same
US8293880B2 (en) * 2008-03-25 2012-10-23 University Of Southern California Prognostic panel for urinary bladder cancer
US8921074B2 (en) * 2008-04-10 2014-12-30 Genenews, Inc. Method and apparatus for determining a probability of colorectal cancer in a subject
RU2517719C2 (ru) * 2008-05-29 2014-05-27 Трансжене Са Биомаркер для отбора пациентов и соответствующие способы
JP5568807B2 (ja) * 2008-06-06 2014-08-13 静岡県 プロテオミクス解析を用いたメラノーママーカーの同定
US10359425B2 (en) 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
MX356367B (es) * 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
US8802384B2 (en) * 2009-03-12 2014-08-12 Boehringer Ingelheim International Gmbh Method or system using biomarkers for the monitoring of a treatment
WO2010118520A1 (en) * 2009-04-16 2010-10-21 National Research Council Of Canada Process for tumour characteristic and marker set identification, tumour classification and marker sets for cancer
US20110064747A1 (en) * 2009-08-25 2011-03-17 Rangaprasad Sarangarajan Methods for treatment of a sarcoma using an epimetabolic shifter (coenzyme q10)
US7736861B1 (en) * 2009-10-19 2010-06-15 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
EP3594356A1 (en) 2009-11-04 2020-01-15 Merck Sharp & Dohme Corp. Engineered anti-tslp antibody
US20120156701A1 (en) * 2009-12-20 2012-06-21 Joseph Anderberg Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX342967B (es) 2009-12-20 2016-10-19 Astute Medical Inc Metodos y composiciones para la diagnosis y prognosis de lesion renal y falla renal.
AU2015202116B2 (en) * 2010-01-11 2017-06-08 Genomic Health, Inc. Method to use gene expression to determine likelihood of clinical outcome of renal cancer
US9551034B2 (en) 2010-01-11 2017-01-24 Genomic Health, Inc. Method to use gene expression to determine likelihood of clinical outcome of renal cancer
JP5947727B2 (ja) 2010-01-20 2016-07-06 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗ｉｌｔ５抗体およびｉｌｔ５結合抗体断片による免疫調節
AU2011207253B2 (en) 2010-01-20 2015-02-12 Merck Sharp & Dohme Corp. Anti-ILT5 antibodies and ILT5-binding antibody fragments
WO2011094483A2 (en) * 2010-01-29 2011-08-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Immune gene signatures in cancer
GB201009798D0 (en) 2010-06-11 2010-07-21 Immunovia Ab Method,array and use thereof
JP5905003B2 (ja) 2010-07-09 2016-04-20 ソマロジック・インコーポレーテッド 肺癌バイオマーカーとその使用
MX350533B (es) * 2010-08-13 2017-09-08 Somalogic Inc Biomarcadores de cancer pancreatico y usos de los mismos.
FR2964744B1 (fr) * 2010-09-10 2015-04-03 Univ Versailles St Quentin En Yvelines Test pronostic de l'evolution d'une tumeur solide par analyse d'images
EP2975399B1 (en) 2010-09-15 2022-05-11 Almac Diagnostic Services Limited Molecular diagnostic test for cancer
JP5784294B2 (ja) * 2010-09-22 2015-09-24 シスメックス株式会社 細胞分析装置および細胞分析方法
ES2816625T3 (es) 2010-09-24 2021-04-05 Niels Grabe Medios y métodos para la predicción de la respuesta a un tratamiento de un paciente con cáncer
EP2625288B1 (en) * 2010-10-08 2016-05-25 Epiontis GmbH Method for determining cancer patient survival based on analyzing tumor-infiltrating overall t-lymphocytes
GB201021289D0 (en) 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
US9593377B2 (en) 2010-12-02 2017-03-14 Dana-Farber Cancer Institute, Inc. Signatures and determinants associated with cancer and methods of use thereof
JP2014505239A (ja) * 2010-12-14 2014-02-27 モアハウス スクール オブ メディスン 癌の治療または検出のための抗ｃｘｃｌ１３および抗ｃｘｃｒ５抗体の使用
EP2663650B1 (en) * 2011-01-11 2016-11-09 INSERM - Institut National de la Santé et de la Recherche Médicale Methods for predicting the outcome of a cancer in a patient by analysing gene expression
EP3693041A1 (en) * 2011-06-13 2020-08-12 TLA Targeted Immunotherapies AB Treating cancer
AR087363A1 (es) * 2011-07-29 2014-03-19 Pf Medicament Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
US9115388B2 (en) 2011-11-01 2015-08-25 H. Lee Moffitt Cancer Center And Research Institute, Inc. Gene signature for the prediction of NF-kappaB activity
US10308980B2 (en) * 2011-11-04 2019-06-04 Oslo Universitetssykehus Hf Methods and biomarkers for analysis of colorectal cancer
EP3540440B1 (en) 2011-12-08 2022-09-28 Astute Medical, Inc. Methods and uses for evaluating renal injury and renal status
JP5970560B2 (ja) * 2012-01-20 2016-08-17 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｂ細胞の密度に基づいて、固形癌に苦しむ患者の生存時間を予測するための方法
EP2805166B1 (en) * 2012-01-20 2018-11-21 INSERM - Institut National de la Santé et de la Recherche Médicale Method for the prognosis of survival time of a patient suffering from a solid cancer
US20130203614A1 (en) 2012-02-08 2013-08-08 Jerome Galon Methods for predicting the survival time of a patient suffering from a solid cancer
ES2902879T3 (es) * 2012-06-14 2022-03-30 Inst Nat Sante Rech Med Método de cuantificación de células inmunitarias en tejidos tumorales y sus aplicaciones
JP6923291B2 (ja) * 2012-07-12 2021-08-18 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 少なくとも７個の遺伝子のサインを用いて、固形癌を患う患者の生存期間および処置に対する応答性を予測するための方法
CN102854322A (zh) * 2012-07-31 2013-01-02 吴克 一种vefg受体酶联诊断试剂盒及其制备方法
LT2880180T (lt) * 2012-08-06 2019-01-25 Institut National De La Santé Et De La Recherche Médicale (Inserm) Būdai ir rinkiniai, skirti vėžiu sergančių pacientų atrankai
ES3015226T3 (en) 2012-08-16 2025-04-30 Veracyte Sd Inc Prostate cancer prognosis using biomarkers
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
DK2914739T3 (da) 2012-11-05 2017-11-27 Novigenix Sa Kombinationer af biomarkører for kolorektale tumorer
CN104937111B (zh) * 2012-11-27 2018-05-11 智利天主教教皇大学 用于诊断甲状腺肿瘤的组合物和方法
WO2014093623A1 (en) * 2012-12-12 2014-06-19 University Of Washington Through Its Center For Commercialization Method and assays for cancer prognosis using jak2
ME03550B (me) 2012-12-17 2020-07-20 Trillium Therapeutics Inc Lečenje cd47+ obolelih ćelija sa sirp alfa-fc fuzijama
JP6681195B2 (ja) 2013-01-17 2020-04-15 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
KR20150122786A (ko) 2013-03-15 2015-11-02 펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나) 암 전이의 진단, 예후 및 치료를 위한 방법
KR20150131269A (ko) * 2013-03-15 2015-11-24 제넨테크, 인크. Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
KR101672531B1 (ko) * 2013-04-18 2016-11-17 주식회사 젠큐릭스 조기 유방암 예후 예측 진단용 유전자 마커 및 이의 용도
US10181008B2 (en) * 2013-05-30 2019-01-15 Genomic Health, Inc. Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
US9851357B2 (en) * 2013-07-15 2017-12-26 Inserm (Institute National De La Sante Et De La Recherche Medicale Method for the prognosis of survival time of a patient suffering from a solid cancer
WO2015057968A2 (en) * 2013-10-17 2015-04-23 The General Hospital Corporation Methods of identifying subjects responsive to treatment for an autoimmune disease and compositions for treating the same
US10344073B2 (en) 2014-01-09 2019-07-09 Hadasit Medical Research Services And Development Ltd. Cell compositions and methods for cancer therapy
JP6605506B2 (ja) 2014-02-24 2019-11-13 ヴェンタナ メディカル システムズ， インク． ＣＤ３、ＣＤ８、ＣＤ２０及びＦｏｘＰ３の同時検出によりがんに対する免疫応答をスコア化するための方法、キット、及びシステム
SG10201807838SA (en) * 2014-03-11 2018-10-30 Council Queensland Inst Medical Res Determining cancer aggressiveness, prognosis and responsiveness to treatment
WO2015157623A1 (en) * 2014-04-11 2015-10-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Immune gene signatures in urothelial carcinoma (uc)
CN106604933B (zh) 2014-07-11 2021-08-10 文塔纳医疗系统公司 抗pd-l1抗体及其诊断用途
WO2016073760A1 (en) * 2014-11-05 2016-05-12 The Regents Of The University Of California Methods for stratifying non-responders to therapies that block pd1/pdl1 axis
KR20170093182A (ko) 2014-12-11 2017-08-14 인바이오모션 에스.엘. 인간 c-maf에 대한 결합 구성원
EP3073268A1 (en) * 2015-03-27 2016-09-28 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Biomarker panel for diagnosing cancer
WO2016181912A1 (ja) * 2015-05-08 2016-11-17 学校法人 川崎学園 免疫因子を指標とした肺腺癌の予後演算式作成方法と予後推定方法
JP6932365B2 (ja) * 2015-05-14 2021-09-08 公立大学法人大阪 スキルス性胃癌の治療剤、及び胃癌の予後の予測方法
EP3304041B1 (en) 2015-05-26 2021-03-10 IncellDx, Inc. Methods of assessing cellular breast samples and compositions for use in practicing the same
US20170038387A1 (en) * 2015-08-04 2017-02-09 Celgene Corporation Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
EP3139170B1 (en) * 2015-08-10 2018-10-03 China Medical University Hospital Method of evaluating glioblastoma multiforme patient applicable to immunotherapy treatment based on dendritic cell tumor vaccines
US10968277B2 (en) * 2015-10-22 2021-04-06 Jounce Therapeutics, Inc. Gene signatures for determining ICOS expression
RU2605310C1 (ru) * 2015-12-01 2016-12-20 Федеральное государственное бюджетное учреждение науки Институт физиологии природных адаптаций Уральского отделения Российской академии наук Способ диагностики риска формирования дефицита противоопухолевой иммунной защиты
PT3384052T (pt) * 2015-12-04 2020-06-08 Singapore Health Serv Pte Ltd Correlatos clínicos de eficácia de imunoterapia
WO2017141988A1 (ja) * 2016-02-19 2017-08-24 コニカミノルタ株式会社 がんまたは免疫系が関係する疾患の診断または治療のための情報取得方法
CN109715653A (zh) * 2016-05-16 2019-05-03 驰科迈博有限责任公司 肿瘤浸润调节性t细胞中被选择性地去调节的标志物
CN105911292B (zh) * 2016-05-19 2018-06-26 深圳市衍生生物科技有限公司 用于组合分析CD11c+CD11b+ DC亚群以及其分化程度和功能的试剂盒及方法
AU2017277305A1 (en) 2016-06-06 2018-12-20 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
US9990713B2 (en) * 2016-06-09 2018-06-05 Definiens Ag Detecting and visualizing correlations between measured correlation values and correlation reference values of a pathway
WO2018027223A1 (en) 2016-08-05 2018-02-08 Duke University Camkk2 inhibitor compositions and methods of using the same
EP3504348B1 (en) 2016-08-24 2022-12-14 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
US20190256603A1 (en) * 2016-11-11 2019-08-22 Medimmune, Llc Anti-pd-l1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
US20190376146A1 (en) * 2016-11-24 2019-12-12 Daiichi Sankyo Company, Limited Method for predicting sensitivity of cancer to treatment with pd-1 immune checkpoint inhibitor
JP7206203B2 (ja) * 2017-02-07 2023-01-17 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル がんの重症度を評価するためのｔｉｍ－３
AU2018230784A1 (en) 2017-03-09 2019-10-10 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
WO2018222718A1 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Treatment of lag-3 positive tumors
JP7301002B2 (ja) 2017-05-30 2023-06-30 ブリストル－マイヤーズ スクイブ カンパニー 抗ｌａｇ－３抗体または抗ｌａｇ－３抗体および抗ｐｄ－１もしくは抗ｐｄ－ｌ１抗体を含む組成物
EP3631468A1 (en) 2017-06-02 2020-04-08 Juno Therapeutics, Inc. Articles of manufacture and methods related to toxicity associated with cell therapy
JP7024957B2 (ja) * 2017-07-04 2022-02-24 株式会社Ｄｎａチップ研究所 大腸癌の異時性転移の有無を予測する方法およびそれに用いるキット
AU2018301704A1 (en) 2017-07-14 2020-03-05 Cofactor Genomics, Inc. Immuno-oncology applications using next generation sequencing
WO2019020556A1 (en) 2017-07-24 2019-01-31 Ventana Medical Systems, Inc. METHODS AND SYSTEMS FOR ASSESSING INFILTRAT OF IMMUNE CELLS IN TUMOR SAMPLES
WO2019028285A2 (en) 2017-08-04 2019-02-07 Genomedx, Inc. USE OF SPECIFIC GENE EXPRESSION OF IMMUNE CELLS FOR THE PROGNOSIS OF PROSTATE CANCER AND THE PREDICTION OF SENSITIVITY TO RADIOTHERAPY
WO2019033043A2 (en) 2017-08-11 2019-02-14 Genentech, Inc. ANTI-CD8 ANTIBODIES AND USES THEREOF
WO2019089858A2 (en) * 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
SG11202003956TA (en) * 2017-11-30 2020-06-29 Singapore Health Serv Pte Ltd A system and method for classifying cancer patients into appropriate cancer treatment groups and compounds for treating the patient
GB201801067D0 (en) 2018-01-23 2018-03-07 Price Nicola Kaye Biomarkers predictive of tumour infiltrating lymphocyte therapy and uses thereof
WO2019149817A1 (en) 2018-01-31 2019-08-08 Ventana Medical Systems, Inc. Methods and systems for evaluation of immune cell infiltrate in stage iii colorectal cancer
JP7458318B2 (ja) 2018-02-12 2024-03-29 ハダシット メディカル リサーチ サービシーズ アンド ディベロップメント リミテッド 癌治療のためのｓｌａｍｆ６スプライスバリアントの調節
WO2019164870A1 (en) * 2018-02-20 2019-08-29 Medimmune, Llc Expression of signature mrnas for identifying patients responsive to anti-pd-l1 antibody therapy
US20210018507A1 (en) * 2018-03-04 2021-01-21 Mazumdar Shaw Medical Foundation Sall.ivary protein biomarkers for the diagnosis and prognosis of head and neck cancers, and precancers
CA3093709C (en) 2018-03-16 2024-03-26 Zoetis Services Llc Peptide vaccines against interleukin-31
CN119656304A (zh) * 2018-04-12 2025-03-21 凯德药业股份有限公司 使用肿瘤微环境的特征的嵌合受体t细胞治疗
WO2019234221A1 (en) * 2018-06-08 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
CN108949982B (zh) * 2018-07-09 2021-10-26 中国医科大学附属第一医院 一种利用免疫共刺激分子评价胶质瘤临床预后的方法
WO2020014666A1 (en) 2018-07-12 2020-01-16 Corvus Pharmaceuticals, Inc. Methods for detecting and treating cancers having adenosine pathway activation
KR102767594B1 (ko) * 2018-07-12 2025-02-12 코버스 파마슈티칼스, 인크. 아데노신 경로 활성화를 갖는 암의 검출 및 치료 방법
EP3861137A4 (en) * 2018-10-01 2022-07-13 Nantomics, LLC Evidence based selection of patients for clinical trials using histopathology
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
KR102198404B1 (ko) * 2019-04-15 2021-01-05 고려대학교 산학협력단 대장암에서 항암제 내성과 관련된 cd133 및 이의 용도
WO2020256868A1 (en) * 2019-05-16 2020-12-24 Trustees Of Boston University Immune system modulators for the treatment of squamous lung premalignancy
WO2020235943A1 (ko) * 2019-05-21 2020-11-26 (주)아큐레시스바이오 암의 진단용 조성물
CN114072676B (zh) 2019-06-03 2024-07-12 法国国家卫生及研究医学协会 调节治疗方案的方法
IL267614A (en) 2019-06-24 2019-09-26 Lotem Michal Nucleic acids to modulate SLAMF6 isoforms
CN110488015A (zh) * 2019-08-27 2019-11-22 成都和同易创生物科技有限公司 趋化因子cxcl14在预测结肠癌预后中的应用
CA3155796A1 (en) * 2019-10-29 2021-05-06 The Board Of Trustees Of The Leland Stanford Junior University Methods of treatments based upon molecular response to treatment
WO2021092071A1 (en) 2019-11-07 2021-05-14 Oncxerna Therapeutics, Inc. Classification of tumor microenvironments
CN110895280B (zh) * 2019-12-03 2022-11-18 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 用于预测鼻咽癌转移的免疫评分及其应用
JP7807372B2 (ja) 2019-12-20 2026-01-27 ハドソン インスティチュート オブ メディカル リサーチ Ｃｘｃｌ１０結合タンパク質及びその使用
KR20220152250A (ko) * 2020-03-06 2022-11-15 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 암을 치료하기 위한 irf 모듈레이터를 발현하는 종양용해성 바이러스
CN111458509B (zh) * 2020-04-14 2023-09-22 中国人民解放军海军军医大学第三附属医院 肝细胞癌预后评估的生物标志物及其试剂盒和方法
JP7741831B2 (ja) 2020-06-30 2025-09-18 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 術前補助療法及び根治手術後の固形がんを患っている患者の再発及び／又は死亡のリスクを予測するための方法
EP4172621A1 (en) 2020-06-30 2023-05-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies
FR3112210A1 (fr) * 2020-07-06 2022-01-07 bioMérieux Procédé pour déterminer le risque de survenue d’une infection associée aux soins chez un patient
CN111638342A (zh) * 2020-07-08 2020-09-08 上海市浦东新区公利医院(第二军医大学附属公利医院) Sox17蛋白在制备肾透明细胞癌诊断或预后评估试剂盒中的应用
CA3196496A1 (en) 2020-10-23 2022-04-28 Laurence David TOMS Lag-3 antagonist therapy for lung cancer
CN112365951B (zh) * 2020-11-24 2024-03-08 竹安（北京）生物科技发展有限公司 一种基于免疫检测的肿瘤用药指导系统及方法
CN112489800B (zh) * 2020-12-03 2024-05-28 安徽医科大学第一附属医院 一种前列腺癌患者的预后评估系统及其应用
KR102427057B1 (ko) * 2020-12-04 2022-07-29 전남대학교산학협력단 단일섬유종양/혈관주위세포종 전이 진단 또는 예후 분석용 바이오 마커 및 이를 이용한 진단방법
JP7719455B2 (ja) * 2020-12-21 2025-08-06 公立大学法人和歌山県立医科大学 がん罹患者の全生存期間を予測する方法
EP4026918A1 (en) * 2021-01-12 2022-07-13 Koninklijke Philips N.V. Prediction of an outcome of a colorectal cancer subject
US20220267445A1 (en) * 2021-02-17 2022-08-25 Novocure Gmbh Methods and Compositions for Determining Susceptibility to Treatment with Checkpoint Inhibitors
CN113025716A (zh) * 2021-03-02 2021-06-25 北京大学第一医院 一种用于人肿瘤分级的基因组合及其用途
KR102865613B1 (ko) * 2021-04-06 2025-09-30 전남대학교산학협력단 암환자의 예후 및 항암 치료에 대한 반응성 예측 방법
WO2022216021A1 (ko) * 2021-04-06 2022-10-13 전남대학교산학협력단 암환자의 예후 및 항암 치료에 대한 반응성 예측 방법
WO2022229136A1 (en) * 2021-04-27 2022-11-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of lymph node metastasis and/or recurrence of patients suffering from a t1 cancer treated by endoscopic resection
CN113834889B (zh) * 2021-09-29 2024-02-13 中国医学科学院北京协和医院 垂体柄阻断综合征生物标志物及其确定方法和应用
US20250304692A1 (en) * 2021-10-29 2025-10-02 La Jolla Institute For Immunology Methods for modulating an immune response to cancer or tumor cells
CN113834941B (zh) * 2021-11-02 2024-01-05 复旦大学附属中山医院 基于b细胞表达的结肠癌预后诊断用标记物及其用途
CN114019163B (zh) * 2021-11-02 2024-07-23 复旦大学附属中山医院 基于活化b细胞表达的结肠癌预后诊断用标记物及其用途
JP7727301B2 (ja) * 2021-11-25 2025-08-21 国立研究開発法人国立がん研究センター がん罹患者の生存期間を予測する方法
US20250035635A1 (en) 2022-03-17 2025-01-30 Institut National De La Sante Et De La Recherche Medicale Methods for predicting response to an immunotherapeutic treatment in a patient with a cancer
CN114657252A (zh) * 2022-04-26 2022-06-24 复旦大学 一种用于脑恶性胶质瘤诊断和预后的趋化因子及其应用
US20260151376A1 (en) 2022-10-20 2026-06-04 Institut National de la Santé et de la Recherche Médicale Combination therapy for the treatment of cancer
WO2024192258A2 (en) * 2023-03-14 2024-09-19 Duke University Methods for assessing immune fitness
KR20240151659A (ko) * 2023-04-10 2024-10-18 연세대학교 산학협력단 폐암 치료의 반응 및 효능 평가와 예후 예측용 바이오 마커
CN116819066A (zh) * 2023-06-30 2023-09-29 复旦大学附属中山医院 肝癌微环境检测试剂盒
WO2025022162A1 (en) 2023-07-26 2025-01-30 Vilnius University Ex vivo cellular model system comprising heterogenous cells from human lung tumor for the evaluation of drug cytotoxicity in vitro and method thereof
WO2025188566A1 (en) * 2024-03-04 2025-09-12 Ludwig Enterprises, Inc. MRNAs DIFFERENTIALLY EXPRESSED IN CANCER
WO2025219595A1 (en) 2024-04-19 2025-10-23 Biper Therapeutics Method for combination treatments using alkynylbenzenesulphonamides for cancer therapy
CN121885197A (zh) * 2026-03-19 2026-04-17 华中科技大学同济医学院附属协和医院 一种结直肠癌术前预后预测方法和装置

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
EP0552108B1 (en) 1992-01-17 1999-11-10 Lakowicz, Joseph R. Energy transfer phase-modulation fluoro-immunoassay
US5556763A (en) * 1992-04-06 1996-09-17 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Evaluation and treatment of patients with progressive immunosuppression
EP0610774B1 (en) * 1993-02-09 2001-03-28 Becton, Dickinson and Company Automatic lineage assignment of acute leukemias by flow cytometry
US5658744A (en) * 1994-07-22 1997-08-19 The United States Of America As Represented By The Department Of Health And Human Services Methods of identifying patients having an altered immune status
AU4977896A (en) * 1995-02-17 1996-09-04 Immunotherapy, Inc. Immunotherapy screening, prognosis, and treatment methods and compositions
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
EP0893507A1 (en) * 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
US6892141B1 (en) 2000-03-17 2005-05-10 Hitachi, Ltd. Primer design system
US6656683B1 (en) * 2000-07-05 2003-12-02 Board Of Regents, The University Of Texas System Laser scanning cytology with digital image capture
WO2002068614A2 (en) * 2001-02-26 2002-09-06 Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) Interferon regulatory factor-1/human estrogen receptor fusion protein and its use for treating carcinomas
FR2821605B1 (fr) * 2001-03-01 2003-05-30 Eads Airbus Sa Procede et dispositif pour accelerer la destruction d'au moins deux vortex dans le sillage d'un mobile, en particulier d'un avion
AR036993A1 (es) * 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
EP1399460A4 (en) 2001-04-27 2005-04-13 Sunnybrook & Women S College H GENESIS ASSOCIATED WITH BREAST CANCER AND THEIR USE
CA2468713A1 (en) 2001-11-30 2003-06-12 University Of Rochester Multiplex real-time quantitative pcr
AU2003206443A1 (en) * 2002-02-20 2003-09-09 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Hedgehog-related prophylaxis, therapy and diagnosis of gi tract carcinogenesis
DE60334303D1 (de) * 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
EP1651247B1 (en) * 2003-07-18 2008-09-10 Schering Corporation Treatment and diagnosis of neoplasms using thymic stromal lymphopoietin
PL1810026T3 (pl) * 2004-10-06 2018-08-31 Mayo Foundation For Medical Education And Research B7-H1 i PD-1 w leczeniu raka nerkowokomórkowego

Also Published As

Publication number Publication date
US20150268245A1 (en) 2015-09-24
DK2420840T3 (en) 2016-02-08
EP3364191A1 (en) 2018-08-22
ES2470165T3 (es) 2014-06-23
EP2420839A2 (en) 2012-02-22
EP2241891A1 (en) 2010-10-20
EP2420837B1 (en) 2014-03-05
WO2007045996A1 (en) 2007-04-26
ES2674560T3 (es) 2018-07-02
EP2420838A3 (en) 2012-09-26
EP3088894A1 (en) 2016-11-02
ES2561527T3 (es) 2016-02-26
EP2733493A1 (en) 2014-05-21
US10191059B2 (en) 2019-01-29
ES2398907T3 (es) 2013-03-22
US11300569B2 (en) 2022-04-12
EP2420836A2 (en) 2012-02-22
JP5256038B2 (ja) 2013-08-07
EP2420839A3 (en) 2012-09-19
EP1777523A1 (en) 2007-04-25
ES2531659T3 (es) 2015-03-18
EP2420840A3 (en) 2012-08-08
EP2420841A3 (en) 2012-09-26
EP2420836B1 (en) 2014-03-05
ES2785033T3 (es) 2020-10-05
EP1943520B1 (en) 2011-09-07
US20220308063A1 (en) 2022-09-29
JP5921602B2 (ja) 2016-05-24
EP2420835A2 (en) 2012-02-22
EP2241891B1 (en) 2012-10-31
EP3088894B1 (en) 2018-03-28
JP2009515148A (ja) 2009-04-09
US20190178892A1 (en) 2019-06-13
US8481271B2 (en) 2013-07-09
EP2420837A3 (en) 2012-05-30
EP2420840B1 (en) 2015-11-11
ES2469102T3 (es) 2014-06-17
EP2420837A2 (en) 2012-02-22
US20140057257A1 (en) 2014-02-27
ES2480690T3 (es) 2014-07-28
JP2014158500A (ja) 2014-09-04
JP5789216B2 (ja) 2015-10-07
EP2420836A3 (en) 2012-05-30
JP2012154944A (ja) 2012-08-16
ATE523786T1 (de) 2011-09-15
ES2374783T3 (es) 2012-02-22
US20090215053A1 (en) 2009-08-27
ES2469103T3 (es) 2014-06-17
EP2420841B1 (en) 2014-12-03
ES2480691T3 (es) 2014-07-28
EP2733493B1 (en) 2016-06-22
EP3715849B1 (en) 2023-08-09
EP2420838A2 (en) 2012-02-22
EP1943520A1 (en) 2008-07-16
EP2420835B1 (en) 2014-03-05
ES2592169T3 (es) 2016-11-28
EP2420838B1 (en) 2014-04-16
EP2420840A2 (en) 2012-02-22
DK2733493T3 (en) 2016-09-19
EP2420835A3 (en) 2012-05-30
EP3364191B1 (en) 2020-03-18
EP3715849A1 (en) 2020-09-30
EP2420839B1 (en) 2014-04-16
EP2420841A2 (en) 2012-02-22

Similar Documents

Publication Publication Date Title
EP2420840A3 (en) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
EP2392678A3 (en) Prognosis prediction for colorectal cancer
WO2004065583A3 (en) Gene expression markers for breast cancer prognosis
WO2005039382A3 (en) Prediction of likelihood of cancer recurrence
WO2006042237A3 (en) B7-h1 and methods of diagnosis, prognosis, and treatment of cancer
MX2009013410A (es) Biomarcadores para predecir capacidad de respuesta anti-tnf o sin capacidad de respuesta.
WO2005020785A3 (en) Discovery of the microorganism that causes the human autoimmune disease, primary biliary cirrhosis
IL182423A0 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
EP4357783A3 (en) Highly sensitive system and methods for analysis of troponin
WO2011046964A3 (en) Inhibitors of bruton's tyrosine kinase
WO2008028968A3 (en) Compounds regulating calreticulin, kdel receptor and/or erp-57 cell surface exposure and uses thereof to evaluate the efficiency of a cancer treatment
WO2009054939A8 (en) Cancer classification and methods of use
EP2527466A3 (en) Genetic variants on CHR2 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
TW201613637A (en) Methods of treating Alzheimer's Disease
WO2005117938A3 (en) Methods of treating ocular conditions
WO2008037700A3 (en) Methods for breast cancer prognosis
WO2008061020A3 (en) Methods of treating, diagnosing or detecting cancer
WO2009085196A8 (en) Methods and compositions for correlating genetic markers with prostate cancer risk
WO2006037462A3 (en) Cancer markers
TW200628156A (en) Combination of a SRC kinase inhibitor and a BCR-ABL inhibitor for the treatment of proliferative diseases
MXPA05014220A (es) Genes regulados en cancer ovarico como objetivos de pronostico y terapeuticos.
WO2006110594A3 (en) Sema4d in cancer diagnosis, detection and treatment
WO2008115710A3 (en) Biomarkers for cancer
EP1968981A4 (en) METHOD FOR THE TREATMENT OF TUMORS WITH AZAXANTHONES